Bristol-Myers Squibb Company (BMY) Rising Before The Market Opens - TheStreet

Trade-Ideas LLC identified

Bristol-Myers Squibb Company

(

BMY

) as a pre-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Bristol-Myers Squibb Company as such a stock due to the following factors:

  • BMY has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $430.0 million.
  • BMY traded 10,197 shares today in the pre-market hours as of 7:44 AM.
  • BMY is up 2.4% today from Friday's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in BMY with the Ticky from Trade-Ideas. See the FREE profile for BMY NOW at Trade-Ideas

More details on BMY:

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The stock currently has a dividend yield of 2.3%. BMY has a PE ratio of 59. Currently there are 8 analysts that rate Bristol-Myers Squibb Company a buy, no analysts rate it a sell, and 5 rate it a hold.

The average volume for Bristol-Myers Squibb Company has been 7.6 million shares per day over the past 30 days. Bristol-Myers Squibb has a market cap of $105.4 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.04 and a short float of 1.5% with 3.81 days to cover. Shares are up 10.4% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Bristol-Myers Squibb Company as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow.

Highlights from the ratings report include:

  • The revenue growth came in higher than the industry average of 6.2%. Since the same quarter one year prior, revenues slightly increased by 7.0%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
  • The current debt-to-equity ratio, 0.49, is low and is below the industry average, implying that there has been successful management of debt levels. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.08, which illustrates the ability to avoid short-term cash problems.
  • The gross profit margin for BRISTOL-MYERS SQUIBB CO is currently very high, coming in at 80.33%. Regardless of BMY's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, BMY's net profit margin of -3.12% significantly underperformed when compared to the industry average.
  • Current return on equity is lower than its ROE from the same quarter one year prior. This is a clear sign of weakness within the company. When compared to other companies in the Pharmaceuticals industry and the overall market, BRISTOL-MYERS SQUIBB CO's return on equity is below that of both the industry average and the S&P 500.
  • Net operating cash flow has significantly decreased to $71.00 million or 93.27% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is significantly lower.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.